Currently Viewing:
Newsroom

Botox Effective in Real-World Settings to Prevent Migraine, Study Says

Allison Inserro
OnabotulinumtoxinA (Botox) showed a sustained reduction in headache-day frequency and significant improvement in quality-of-life measures in patients with chronic migraine followed for 2 years, according to a recent study looking at real-world effects.
Real-world preventive treatment of chronic migraine with onabotulinumtoxinA (Botox) showed a sustained reduction in headache-day frequency and significant improvement in quality-of-life measures, according to a recent study looking at results over 2 years.

In the REPOSE study (REal-life use of botulinum toxin for the symptomatic treatment of adults with chronic migraine, measuring healthcare resource utilization, and Patient-reported OutcomeS observed in practice), patients received an injection every 12 weeks. The study was a European, open-label, multicenter, prospective, noninterventional study.

Of 641 patients enrolled, 633 received at least 1 dose of onabotulinumtoxinA for a total of 3499 treatment sessions. At baseline, mean (SD) age was 45.4 (11.7) years; most patients were women (85.3%). Injection practices closely followed the packaging insert in mean dosage (155.1 U) and injection sites per session (31.4), with the exception of a prolongation of the recommended 12-week dosing interval, with 79.1% of patients receiving at least 1 treatment session that was more than 13 weeks after the previous treatment session.

Headache-day frequency was reduced from a baseline mean (SD) of 20.6 (5.4) days to 7.4 (6.6) days at administration visit 8 (P <.001). Each domain on the Migraine-Specific Quality-of-Life Questionnaire—restrictive, preventive, and emotional—was significantly reduced from baseline through each administration visit (P <.001).

In addition, the median EuroQol 5-Dimension Questionnaire total and health state scores were significantly improved from baseline through each administration visit (P <.001).

Overall, 18.3% of patients reported an adverse drug reaction (ADR). Most ADRs were mild to moderate, with only 1.3% of patients reporting a serious ADR. Eyelid ptosis (5.4%), neck pain (2.8%), and musculoskeletal stiffness (2.7%) were the most frequently reported ADRs.

No new safety concerns were identified.

Other preventative treatments for migraine include calcitonin gene-related peptide inhibitors. Earlier this year, the American Headache Society noted that Botox does not require a gradual dose escalation for injectable use and has a rapid onset of benefits.

Reference

Ahmed F, Gaul C, García-Moncó JC, Sommer K, Martelletti P. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study [published online March 7, 2019]. J Headache Pain. doi: 10.1186/s10194-019-0976-1.

Related Articles

Study Identifies Association Between Migraine History, Brain Tumors
Significant Migraine Burden Observed in Patients With at Least 4 Monthly Migraine Days and Prophylactic Treatment Failure
Current, New, and Emerging Therapies for the Prevention and Management of Migraine
Review Find Moderate Evidence That Aerobic Exercise Lowers Number of Migraine Days
Concurrent Mood Disorders Impact Migraine Frequency, Duration of Attack
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up